Edition:
India

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

18.36USD
10:08pm IST
Change (% chg)

$-1.45 (-7.32%)
Prev Close
$19.81
Open
$19.55
Day's High
$19.55
Day's Low
$18.15
Volume
5,112
Avg. Vol
22,623
52-wk High
$25.00
52-wk Low
$12.05

Chart for

About

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory.... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $147.44
Shares Outstanding(Mil.): 14.11
Dividend: --
Yield (%): --

Financials

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

27 Sep 2018

UPDATE 1-Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the country's patients with the drug.

27 Sep 2018

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

27 Sep 2018

Earnings vs. Estimates